Human Primary Liver Cancer-derived Organoid Cultures for disease modelling 1 and drug screening 2 3 4 5

[1]  Tara Srinivasan,et al.  Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing , 2017, Nature Medicine.

[2]  D. Weitz,et al.  An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma , 2017, Proceedings of the National Academy of Sciences.

[3]  Hans Clevers,et al.  Tissue-specific mutation accumulation in human adult stem cells during life , 2016, Nature.

[4]  Hayley E. Francies,et al.  Drug Sensitivity Assays of Human Cancer Organoid Cultures. , 2016, Methods in molecular biology.

[5]  Hans Clevers,et al.  Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation , 2016, Nature Protocols.

[6]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[7]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[8]  M. Aglietta,et al.  Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient , 2015, Tumor Biology.

[9]  Sara R. Selitsky,et al.  Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells , 2015, Nature Communications.

[10]  Bon-Kyoung Koo,et al.  Modeling mouse and human development using organoid cultures , 2015, Development.

[11]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[12]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[13]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[14]  Hans Clevers,et al.  Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver , 2015, Cell.

[15]  Seung Duk Lee,et al.  Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[16]  Nansheng Chen,et al.  Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.

[17]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[18]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[19]  J. Gough,et al.  The ‘dnet’ approach promotes emerging research on cancer patient survival , 2014, Genome Medicine.

[20]  Yupo Ma,et al.  Stem cell gene SALL4 in aggressive hepatocellular carcinoma: A cancer stem cell‐specific target? , 2014, Hepatology.

[21]  H. Aburatani,et al.  Exploration of liver cancer genomes , 2014, Nature Reviews Gastroenterology &Hepatology.

[22]  Olivier Gevaert,et al.  Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture , 2014, Nature Medicine.

[23]  C. Wongkham,et al.  A Novel Predictive Equation for Potential Diagnosis of Cholangiocarcinoma , 2014, PloS one.

[24]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[25]  Hans Clevers,et al.  Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis , 2013, The EMBO journal.

[26]  Guan-Cheng Li,et al.  Tumor markers for hepatocellular carcinoma , 2013, Molecular and clinical oncology.

[27]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[28]  Hans Clevers,et al.  In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration , 2013, Nature.

[29]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[30]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[31]  T. Limpaiboon,et al.  A novel TFF2 splice variant (ΔEX2TFF2) correlates with longer overall survival time in cholangiocarcinoma , 2011, Oncology reports.

[32]  Hans Clevers,et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.

[33]  Michael A Choti,et al.  Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.

[34]  S. Hsieh,et al.  Stathmin1 overexpression associated with polyploidy, tumor‐cell invasion, early recurrence, and poor prognosis in human hepatoma , 2010, Molecular carcinogenesis.

[35]  Jung-Hwan Yoon,et al.  Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.

[36]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[37]  Anne C. Kubisch,et al.  Evaluating Complex Systems-Building Initiatives , 2008 .

[38]  W-H Kim,et al.  Establishment and characterisation of six human biliary tract cancer cell lines , 2002, British Journal of Cancer.

[39]  Y. Matsuo,et al.  p53 alterations in human leukemia–lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? , 2000, Leukemia.

[40]  Kol Jia Yong,et al.  Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. , 2013, The New England journal of medicine.

[41]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[42]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[43]  H. Kaiser,et al.  Pattern of Metastasis , 1989 .